Recent Report on Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

To access full report with TOC, please visit Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 29, 21, 3, 106, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 29 and 6 molecules, respectively.Type 1 Diabetes (Juvenile Diabetes).

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

AbGenomics International, Inc. Adocia AiCuris GmbH and Co KG Alteogen Inc. Amarantus Bioscience Holdings, Inc. Ambrx, Inc. AntriaBio, Inc. Aphios Corporation APT Therapeutics, Inc. Araim Pharmaceuticals, Inc. Argos Therapeutics, Inc. Artery Therapeutics, Inc. Astellas Pharma Inc. AstraZeneca Plc Athersys, Inc. Atlantic Bio Sci LLC Axxam SpA Beta-Cell NV Biocon Limited Biogenomics Limited BioLineRx, Ltd. BioLingus AG BioTherapeutics Inc. BirchBioMed Inc Boehringer Ingelheim GmbH Caladrius Biosciences Inc Cancer Prevention Pharmaceuticals, Inc. Carlina Technologies SAS Compugen Ltd. ConjuChem, LLC Daewoong Pharmaceutical Co., Ltd. Dance Biopharm Inc. Diabetology (Products) Ltd DiaMedica Inc. Diamyd Medical AB Diasome Pharmaceuticals, Inc. Dompe Farmaceutici S.p.A. Eli Lilly and Company enGene, Inc Ensol Biosciences Inc. EpiVax, Inc. Escape Therapeutics, Inc. Evotec AG F. Hoffmann-La Roche Ltd. Fate Therapeutics, Inc. Generex Biotechnology Corporation GeNeuro SA Geropharm Gilead Sciences, Inc. GlaxoSmithKline Plc Grifols, S.A. Heptares Therapeutics Limited Iltoo Pharma ImmusanT, Inc. Innopharmax Inc. Intrexon Corporation Islet Sciences, Inc. Johnson & Johnson Kadimastem Ltd. Kamada Ltd. Kasiak Research Private Limited KPI Therapeutics, Inc. Lexicon Pharmaceuticals, Inc. Ligand Pharmaceuticals, Inc. Lonestar Heart, Inc. MacroGenics, Inc. Medestea Research & Production S.p.A. MedImmune LLC Medy-Tox Inc. Merck & Co., Inc. Meridigen Biotech Co., Ltd. MidaSol Therapeutics LP Mitsubishi Tanabe Pharma Corporation Novo Nordisk A/S Noxxon Pharma AG Oramed Pharmaceuticals, Inc. Orgenesis Inc OSE Immunotherapeutics Paras Biopharmaceuticals Finland Oy Parvus Therapeutics, Inc. Pathfinder Cell Therapy Inc Pfizer Inc. PharmaCyte Biotech, Inc. PharmaIN Corporation Prometheon Pharma, LLC Purzer Pharmaceutical Co., Ltd. RedHill Biopharma Ltd. REGiMMUNE Corporation Sanofi SEKRIS Biomedical, Inc. Selecta Biosciences, Inc. Semma Therapeutics Inc. Sevion Therapeutics, Inc. Strongbridge Biopharma plc Therapix Biosciences Ltd. Thermalin Diabetes, LLC Toleranzia AB Transgene Biotek Limited UCB SA Unicyte AG United Therapeutics Corporation ViaCyte, Inc. Visionary Pharmaceuticals, Inc. XL-protein GmbH XOMA Corporation Zensun (Shanghai) Sci & Tech Co., Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###